Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab in Malignant Pleural Mesothelioma
NCT03075527Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Apr 2017
- Primary completion
- Jun 2019
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in malignant pleural mesothelioma (MPM), sponsored by Dana-Farber Cancer Institute. Started Apr 2017; status: terminated.
02
Drugs
durvalumabtremelimumab
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT03075527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03075527.